Unlike type II cancers, which nearly always contain TP53 mutations (94% of the type II cancers we studied, for example), the genomic landscapes of type I cancers and borderline tumors are more heterogeneous and not as well studied (Kurman and Shih, 2010). The gene discussed is TP53; the disease is cancer.